SCHEMBL3240375

SCHEMBL3240375

CSc1ccccc1C(=O)N1N(C2C3CC4CC(C3)CC2C4)C(=O)C1(C)C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.44
HTT P42858 2/20 0.42
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 5/20 0.39
GAA P10253 3/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 3/20 0.37
LMNA P02545 3/20 0.37
MAPK1 P28482 1/20 0.35
USP2 O75604 1/20 0.35
PREP P48147 1/20 0.35
HCRTR2 O43614 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169693 0.85 ITGB1 (0.42) HTTALDH1A1KMT2AHPGDMEN1
SCHEMBL2172271 0.85 KDM4E (0.39) HSD17B10HTTALDH1A1KMT2AGAA
SCHEMBL2170645 0.84 GAA (0.45) ALDH1A1GAALMNAUSP2HCRTR2
SCHEMBL2168643 0.84 USP2 (0.36) ALDH1A1GAAUSP2
SCHEMBL2170594 0.84 USP2 (0.36) HSD17B10ALDH1A1GAAUSP2PREP
SCHEMBL2169957 0.84 EPHX2 (0.39) HTTALDH1A1KMT2AMEN1USP2
SCHEMBL2170385 0.84 P2RX7 (0.39) KMT2AGAAMEN1USP2
SCHEMBL2168761 0.83 HCRTR1 (0.37) HSD17B10ALDH1A1KMT2AGAAMEN1
SCHEMBL2169849 0.82 FAAH (0.44) HTTALDH1A1KMT2AMEN1LMNA
SCHEMBL2189492 0.82 HSD17B10 (0.44) HSD17B10HTTALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US claimed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US claimed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 HSD17B10 14/4885HTT 2903/4885ALDH1A1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.